Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Family presence during resuscitation of a child remains controversial and disagreement persists about whether and when potential benefits outweigh risks.
AMA J Ethics. 2018;20(5):507-512. doi:
10.1001/journalofethics.2018.20.5.sect1-1805.
Peter Ellis, MD, MPH and Lydia S. Dugdale, MD, MAR
Presenting all, including expensive, options to all patients means advocating not only for individual patients, but also for a just health care system.
AMA J Ethics. 2019;21(1):E26-31. doi:
10.1001/amajethics.2019.26.
Going to so-called safety-net clinics could mean being subject to different standards of care than those in other health care delivery settings. Learners who understand social determinants of health might be able to help patients navigate the system and access community resources.
AMA J Ethics. 2019;21(1):E44-49. doi:
10.1001/amajethics.2019.44.